Insider Selling: MiNK Therapeutics (NASDAQ:INKT) Director Sells 1,500 Shares of Stock

MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Barbara Ryan sold 1,500 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $12.76, for a total transaction of $19,140.00. Following the completion of the sale, the director directly owned 21,969 shares of the company’s stock, valued at approximately $280,324.44. This trade represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Barbara Ryan also recently made the following trade(s):

• On Tuesday, March 10th, Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock. The shares were sold at an average price of $15.40, for a total transaction of $20,020.00.
• On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The shares were sold at an average price of $10.17, for a total value of $2,034.00.

MiNK Therapeutics Stock Performance

NASDAQ INKT traded down $0.88 on Friday, reaching $11.87. 51,453 shares of the stock traded hands, compared to its average volume of 187,181. The company has a fifty day moving average price of $11.35 and a 200-day moving average price of $11.37. The company has a market cap of $59.11 million, a price-to-earnings ratio of -4.18 and a beta of 0.47. MiNK Therapeutics, Inc. has a 12 month low of $6.80 and a 12 month high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last issued its earnings results on Friday, May 15th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.20. As a group, research analysts anticipate that MiNK Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC bought a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on INKT. Weiss Ratings raised MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a research report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, MiNK Therapeutics has a consensus rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell?to?cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor?associated macrophages and boost T cell–mediated tumor clearance.